Kornimate/medical-research-clean huggingface dataset:
investigating the effects of hydroxyvitamin d3 on multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting; Adult ALL; Vitamin D3 Deficiency

Summary: investigating the effects of hydroxyvitamin d3 on clinical, radiologic and immunomodulatory markers in ms patients: a randomized, clinical trial- a pilot study

vitamin d deficiency/insufficiency is a risk factor for developing ms and is linked to increased disease activity in those with established disease. several clinical trials have already been conducted to consider the effect of vitamin d supplementation on clinical outcomes of the disease but the findings were inconsistent. this paradox may be explained by supplementation dose, trial duration and also an insufficient rise in serum 25-hydroxyvitamin d to be effective on immunomodulatory pathways and consequent clinical outcomes. of note, it was revealed that ms patients have a lower rise in serum 25-hydroxyvitamin d \[25(oh)d\] levels compared with healthy controls (hcs), when given the same amount of oral cholecalciferol supplementation. cholecalciferol is the main vitamin d supplement that was used in these trials. when vitamin d3 is ingested, it is incorporated into chylomicrons and enters the lymphatic system. the chylomicrons then enter into the bloodstream via the superior cava. most of the vitamin d is incorporated into the body fat. vitamin d3 in the circulation and the vitamin d3 that is slowly released from the body fat into the circulation is converted in the liver to 25(oh)d3, taking approximately 6-8 weeks to achieve a steady state concentration of 25(oh)d3. the more rapid increase in serum concentrations of 25(oh)d3, by treatment with calcifediol instead of cholecalciferol, may provide an advantage through rapid entry into its target innate and adaptive immune cells, resulting in the paracrine/autocrine production of 1α,25(oh)2d which interacts with the vitamin d receptor (vdr) to modulate immune function.

Eligibility criteria:
inclusion criteria: 1. ms type: relapsing-remitting ms (rrms) 2. older than 18 year-old 3. vitamin d deficiency/insufficiency (25(oh)d\<30 ng/ml exclusion criteria: 1. medications or disorders that would affect vitamin d metabolism 2. history of other chronic disorders 3. history of conditions that could lead to high serum calcium levels 4. pulse therapy in the last 3 months 5. history of attack in the last 3 months 6. using corticosteroid in the last 3 months 7. be pregnant
the status of asthma in the korean military personnel

Conditions: Asthma

Summary: the aim of this study is to evaluate the status of allergic diseases in the korean military personnel.

isaac (international study of asthma and allergies in childhood) questionnaires are sent to military personnel in the republic of korea. military personnel are randomly selected representative of the number of soldiers in each area. we perform methacholine provocation test and mast for current wheezer after informed consents.

Eligibility criteria:
inclusion criteria: * korean military personnel who can respond questionnaire exclusion criteria: * person who refuse to participate in this study

Keywords: asthma allergic rhinitis military
treatment of pcnsl with r-idaram and intrathecal immunochemotherapy

Conditions: Primary Central Nervous System Lymphoma

Summary: this study suggests that r-idaram combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (pcnsl) patients.

the investigators will evaluate response rate, progression free survival (pfs), overall survival (os), and toxicity in primary central nervous system lymphoma (pcnsl) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.

Eligibility criteria:
inclusion criteria: * newly diagnosed histologically proven non-hodgkin's lymphoma (nhl). exclusion criteria: * involved sites other than the brain, meninges, csf, or the eyes. * age less than 18 years or greater than 75 years. * inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/l, platelets \<100 ×10\^9/l, and hemoglobin level\< 8 g/dl). * known cause of immunosuppression (ie, hiv type i infection). * any previous malignancy. * creatinine clearance below 60 ml/min. * heart insufficiency (nyha iiib or iv). * uncontrolled infection. * noncompensated active pulmonary or liver disease. * previously treated for pcnsl, except by corticosteroids.
use of sildenafil (viagra) to alter fatigue, functional status and impaired cerebral blood flow in patients with cfs

Conditions: Chronic Fatigue Syndrome

Summary: use of viagra to alter symptoms in patients with chronic fatigue syndrome (cfs)

use of sildenafil (viagra) to alter fatigue, functional status and impaired cerebral blood flow in patients with chronic fatigue syndrome.

Eligibility criteria:
inclusion criteria: * patients meeting the cdc definition of cfs. * all races, ethnicities, socio-economic status (ses), and gender * age greater than 18 (because of concerns about radioactivity, we and the cedars-sinai and harbor-ucla irbs have decided not to enroll subjects below the age of 18). * age less than 50. because of concern of sildenafil exacerbating coronary artery disease, we will only enroll patients younger than 50. * able to provide informed consent. * willingness to be off all medicines and supplements for 3 weeks prior to the study. * patients with psychiatric disorders (see below) will be included, if they could be off their medications, and if their psychiatric diagnosis clearly occurred after their fatigue symptoms began. * patients with concurrent fibromyalgia will be allowed to participate if the meet diagnostic criteria for cfs. exclusion criteria: * disabilities that would prevent them from participating in the study. * current use of prescription medicines (starting at 3 weeks prior to the study) and supplements (starting at 1 weeks prior to the study) except acetaminophen or aspirin. this includes herbal supplements and vitamins. * existing medical illnesses, such as heart disease, hypertension, cancer, rheumatological diseases, endocrinopathies or hormone replacement therapy, seizure disorders, severe obesity (bmi \> 32 kg/m2), * severe psychiatric disorders including bipolar disorder, schizophrenia, dementia and previous or current diagnosis of alcohol or substance abuse within the past year. patients with depression of such severity as to warrant treatment with anti-depressants will be excluded. * current abuse of illicit drugs or heavy ethanol use. * pregnant women will be excluded because of radioactivity exposure from the spect scans. * abnormal ekg * abnormal cbc, blood chemistries, thyroid function tests, and hiv, ana, rf and esr tests.
open discectomy versus microscopic discectomy for lumbar disc herniation

Conditions: Lumbar Disc Herniation

Summary: 60 patients involved were divided into two matched groups; group a: 30 patients were treated with conventional fenestration laminectomy and discectomy and group b: 30 patients were treated with microdiscectomy. the age of the patients involved in this study ranged from 19 years old to 46 years old

60 patients involved were divided into two matched groups; group a: 30 patients were treated with conventional fenestration laminectomy and discectomy and group b: 30 patients were treated with microdiscectomy. the age of the patients involved in this study ranged from 19 years old to 46 years old. all the patient was suffering from symptomatic lumbar disc herniation l4-5. each patient was assessed clinically and mri was done for all the patients to prove clinically, the symptomatic lumbar disc herniation which was present in all patients.

Eligibility criteria:
inclusion criteria: * adults who are symptomatic lumbar disc herniation l4-5. each patient was assessed clinically and mri was done for all the patients to prove clinically, the symptomatic lumbar disc herniation which was present in all patients. conservative treatment for 6weeks was failed exclusion criteria: * smoking, previous lumbar spine surgery, diabetes melitus (dm) and neuromuscular disorders.

Keywords: lumbar disc herniation , open discectomy, micrdiscectomy
effect of local warming for arterial catheterization in pediatric anesthesia

Conditions: Congenital Heart Disease

Summary: the increase in internal diameter (id) and cross-sectional area (csa) may facilitate better arterial catheterization. since an increase in body temperature can cause peripheral vasodilation, we aimed to determine if local warming of the radial artery (ra) catheterization site could improve the success rate of catheterization in pediatric patients.

this randomized, controlled study enrolls 126 pediatric patients aged ≤ 2 years who were scheduled for heart surgery. they are randomized into non-warming (c) and warming (w) groups. after induction, the baseline artery ultrasonography images are collected. in the warming group (w), local warming is applied on the catheterization site. before catheterization, the artery ultrasonography images are collected. the primary outcome is the first-attempt success rate. the secondary outcomes included the id and csa of the artery and overall complications.

Eligibility criteria:
inclusion criteria: * aged ≤ 2 years * cardiac surgery with peripheral artery catheterization exclusion criteria: * unstable vital signs * pre-existing arterial catheter (exception of umbilical artery catheterization)
an exploratory, double-blind, placebo-controlled study of the medical food vayarin in children with autism spectrum disorder (asd)

Conditions: Autistic Disorder

Summary: the primary study objective is to evaluate the efficacy of vayarin_005 on asd related symptoms in children.


Eligibility criteria:
inclusion criteria: 1. males or females, ages 6-17 inclusive 2. must have a valid diagnosis of autism spectrum disorder via a clinical review of the dsm-iv, confirmed by autism diagnostic observation schedule (ados) 3. clinical global impression scale of severity of illness for pervasive developmental disorders (cgi-s-pdd) rating of 4 or higher (moderately ill or worse) 4. iq \>50 evaluated by kbit-2 or stanford binet fifth edition 5. able, and likely to fully comply with the study procedures and instructions 6. subjects with mood, anxiety, or disruptive behavior disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria. 7. have normal physical examination and laboratory test results at screening. if abnormal, the finding(s) must be deemed clinically insignificant by the study clinician. 8. parents or legal guardian must be able to read, write and speak english 9. parents or legal guardian have given written informed consent to participate in the study exclusion criteria: 1. the subject is significantly underweight under the 5th percentile or obese above the 95th percentile 2. clinically significant systemic illness including hepatic, renal, gastroenterological, metabolic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease, as determined by the study clinician. 3. patients with any primary psychiatric diagnosis other than autism at screening or a known genetic syndrome(s) that cause autism. 4. suspected or established cns injury 5. change in dosage of psychiatric pharmacotherapy or other medications that have central nervous system effects or that affect performance 4 weeks before study initiation and throughout the study phase 6. use of alpha-agonists, or adhd medications 4 weeks prior to study initiation and throughout the study 7. use of dietary supplements, 60 days before study initiation and throughout the study 8. change in educational/behavioral interventions within one month prior to participation or during the study 9. a known comorbid psychiatric diagnoses of bipolar i disorder, suicidality, or substantial psychotic disorder. 10. subject who has participated in another clinical trial within 30 days of screening for this trial and/or any experimental treatment for this population 11. current history of physical, sexual, or emotional abuse 12. history of alcohol or substance abuse as defined by dsm-iv criteria 13. consumption of \>250 mg/day of caffeine 14. history of allergic reactions or sensitivity to marine products and soy 15. has any illness which may jeopardize the participants' health or limit their successful trial completion. 16. any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the patient safety
sasl swiss cirrhosis cohort

Conditions: Liver Cirrhosis

Summary: this is a national prospective long-term multicentre observational cohort study following patients with cirrhosis in order to systematically and longitudinally record epidemiological, clinical, histological, psychosocial and patient-reported data and biobank biological material from patients with cirrhosis. the central element of all scientific operation and productivity in the swiss cirrhosis cohort study (sscicos) is the so-called "nested project" (np). based on the evolving large pool of data and biological samples, sscicos investigators use the data pool in order to investigate specific hypotheses and questions.

for patients with end-stage cirrhosis there are no treatment options other than transplantation, a medically and ethically challenging procedure. the challenge therefore is to prevent the need for liver transplantation in as many patients with cirrhosis as possible. in order to reach this aim, patients with cirrhosis should be identified and followed regularly according to the highest standard of current knowledge. numerous aspects of the disease need to be detailed: its epidemiology in switzerland, its pathophysiology including the mechanism of scar tissue generation and resolution, the associated immune dysfunction and subsequent organ failures, disease related psychosocial and behavioural factors, perceived burden of liver cirrhosis in patients, diagnostic and prognostic biomarkers for disease dynamics, both progression and regression of disease, and stage-specific therapeutic strategies. this is a national prospective long-term multicentre observational cohort study following patients with cirrhosis in order to systematically and longitudinally record epidemiological, clinical, histological, psychosocial and patient-reported data and biobank biological material from patients with cirrhosis.

Eligibility criteria:
inclusion criteria: * a) patients with chronic liver disease and histologically proven cirrhosis * b) control subjects with no signs of cirrhosis exclusion criteria: * age \<18 years * patients who developed hepatocellular carcinoma (hcc) and/or cholangiocellular carcinoma (ccc)

Keywords: sasl swiss cirrhosis cohort study (sscicos) chronic liver disease
clonal hematopoiesis of indeterminate potential in heart failure.

Conditions: Heart Failure

Summary: this study is part of the rico macro-project, a multidisciplinary research program promoted by from in collaboration with the asst-pg23 and ats bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (hematology, cardiology, neurology, pneumology, gastroenterology, and diabetology, etc.). in this context, the prospective observational study rico-hf is developed. the rico hf is the first project focused on chip and inflammation in the area of cardiology, specifically in hf.

chip is associated with a pro-inflammatory state and its mechanistic link to hf has been demonstrated in animal and cellular models, and in patient cohorts (14-24). although hf in humans has various causes, different pathophysiological mechanisms and heterogeneous clinical manifestations, the experimental and clinical data reported so far support the relevance of inflammatory cytokine production and signaling by immune cells in the pathogenesis of cardiac dysfunction and hf.

Eligibility criteria:
inclusion criteria: * consecutive patients admitted to the cardiology unit of the asst papa giovanni xxiii hospital, bergamo for acute hf and patients attending the outpatient hf clinic of the same hospital for chronic hf * age \>18 years * written informed consent exclusion criteria: * chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents * previous heart transplant * cardiogenic shock or cardiac arrest * recent acute coronary syndrome (\<3 months) * current acute infection requiring specific treatment * overt mpns * primary myelodysplastic syndromes * malignant cancers * non-cardiovascular co-morbidity reducing life expectancy to \< 1 year * any factor precluding 1-year follow-up
a safety and efficacy study of the birmingham hip resurfacing system

Conditions: Arthritis

Summary: the purpose of this study is to meet a pma condition of approval of the bhr system. the study will evaluate the long term safety and effectiveness of the bhr system in patients with non-inflammatory and inflammatory arthritis.

this is a post-approval, prospective, non-randomized, longitudinal, unmasked, multi-center, clinical trial designed to evaluate the longer-term safety and effectiveness of the bhr system. the data collected will permit clinical evaluation for the device performance in improving hip pain, function and range of motion through ten years. the study will permit radiographic evaluation of proper component fixation and alignment maintenance through 10 years post-operative. the incidence of revision is an especially important measure in this study. data collected will allow analysis of the implant survivorship.

Eligibility criteria:
inclusion criteria: * at least 21 years of age and skeletally mature * patients requiring primary hip resurfacing due to: * non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, avascular necrosis, or dysplasia/ddh * inflammatory arthritis such as rheumatoid arthritis * subject or his/her legal guardian is willing to consent to participate in the study by signing and dating the approved consent form * subject is available for clinical follow-up through at least ten years * subject meets none of the exclusion criteria exclusion criteria: * subjects with infection or sepsis * subjects with any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery * female subjects of child-bearing age * subjects with bone stock inadequate to support the device * subjects with known moderate to severe renal insufficiency * subjects with known or suspected metal sensitivity (e.g. jewelry) * subjects who are immunosuppressed with diseases such as aids or persons receiving high doses of corticosteroids * subjects with psychological or neurological conditions which would pre-empt their ability or unwillingness to participate in the study * subjects who are severely overweight
impact of nonsurgical periodontal therapy on oral health related quality of life

Conditions: Periodontitis

Summary: periodontitis is a destructive inflammatory disease of tooth supporting tissues and it adversely affects oral and general health as well as lowering the quality of life. nonsurgical periodontal therapy is a gold standard technique for treating mild to moderate periodontitis and it was reported to significantly improve oral health related quality of life.

periodontitis is a chronic disease characterized by progressive loss of tooth-supporting tissues. it is adversely affecting function, esthetic, and general wellbeing. oral health related quality of life (ohrqol) is the part of quality of life which is affected by oral cavity-related status. majority of clinical studies emphasize on periodontal outcomes after periodontal therapy. however, tangible outcomes perceived by the patient such as need for re-treatment, tooth survival, and ohrqol are mostly neglected. ohrqol is mainly measured by using self-reported questionnaires and the most commonly used one is oral health impact profile (ohip). nonsurgical periodontal therapy (nspt) is the gold-standard technique for treating shallow to moderately deep periodontal pockets. the principle of this technique is based on mechanically disrupting subgingival dysbiotic biofilm, consequently; restoring homeostasis and healthy state of periodontal tissues. indeed, halting progressive periodontitis is a major contributor for improving oral health and increasing tooth survival rate which are positively perceived by the patients. previous studies consistently reporting improvement of ohrqol following periodontal treatment. therefore, this study aimed to investigate the impact of nspt on ohrqol for stage (s)2 and s3 periodontitis patient and the factors predicting the outcomes.

Eligibility criteria:
inclusion criteria: * adults (\>18 years) * not reporting history of any systemic disease * non-smoker * can read and understand the questionnaire. exclusion criteria: * patients with depression or any psychological issues * those not willing to participate
culprit-first in primary percutaneous coronary intervention

Conditions: Coronary Artery Disease; Ischemic Heart Disease; Myocardial Infarction; STEMI; Stent

Summary: the aim of this study is to assess the impact of culprit-first versus culprit-last percutaneous coronary intervention on the door to balloon time and clinical outcomes in patients with st-elevation myocardial infarction.

ischemic heart disease (ihd) is the single most common cause of death and its frequency is increasing globally. it is estimated that ihd is the cause of 1.8 million deaths or 20% of all deaths in europe. despite advancements in the fields of rapid diagnosis and in treatment strategies, the morbidity, and mortality in patients with st-segment myocardial infarction remains substantial, with an estimated mortality rate of 4-12% according to registries of the esc countries. according to the 2017 european society of cardiology (esc) guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation (stemi), there is a level 1 recommendation with a level of evidence a for primary percutaneous coronary intervention (ppci) strategy in patients with stemi, and this strategy is preferred over fibrinolytic therapy. in addition, the esc guidelines recommend a first medical contact to reperfusion time within 60 minutes in stemi patients for primary pci-capable centers. this recommendation is supported by a recently published study that showed shortening door to balloon (d2b) time was significantly associated with survival benefit. based on the recommendation for maximal d2b time in stemi patients to be 60 minutes, many countries and institutions worldwide have established programs, among them the national program for quality indicators by the israeli ministry of health, to shorten d2b times. according to data published by the israeli ministry of health in the year 2018, 88% of stemi patients had a d2b time of \<90 minutes. the common practice during ppci is to complete diagnostic angiography of the whole coronary tree before performing culprit-vessel revascularization. this practice is not evidence-based and current guidelines do not prioritize full diagnostic angiography over culprit-vessel revascularization first. as was found in previous studies, this practice might result in delaying revascularization by 4-8 minutes in d2b time. this delay might potentially lead to worse outcomes in stemi patients, although not proven in the above-cited studies.

Eligibility criteria:
inclusion criteria: * patients presenting with stemi who are eligible for ppci exclusion criteria: * cardiac arrest * cardiopulmonary resuscitation or extracorporeal membrane oxygenation on arrival to the catheterization laboratory * prior coronary artery bypass grafting surgery

Keywords: coronary artery disease stemi primary pci door-to-balloon time